Johnson & Johnson To Present New Findings On IMAAVY For Treatment Of Generalized Myasthenia Gravis Across 15 Novel Abstracts At 2026 MGFA Scientific Session And AANEM Annual Meeting

Johnson & Johnson (NYSE: JNJ) announced new findings on IMAAVY (nipocalimab-aahu) for treating generalized myasthenia gravis (gMG), to be presented in 15 abstracts at the 2026 MGFA Scientific Session and AANEM Annual Meeting. The two-year Phase 2/3 study results in adolescents showed sustained disease control, improved daily function, increased muscle strength, and reduced corticosteroid use. Additionally, a retrospective survey highlighted fluctuating symptom control as a key factor for patients transitioning to IMAAVY from other treatments.